参考文献/References:
[1] 中华医学会神经病学分会.中华医学会神经病学分会脑血管病学组.中国蛛网膜下腔出血诊治指南2015[J].中华神经科杂志,2016,49(3):182-191.
[2] Macdonald RL,Schweizer T.Spontaneous subarachnoid haemorrhage[J].Lancet,2017,389(10069):655-666.
[3] 齐猛,史继新.蛛网膜下腔出血患者贫血的研究进展[J].中国脑血管病杂志,2012,9(1):48-50.
[4] Kramer AH,Gurka MJ,Nathan B,et al.Complications associated with anemia and blood transfusion in patients with aneurysmal subarachnoid hemorrhage[J].Crit Care Med,2008,36(7):2070-2075.
[5] Kramer AH,Zygun D,Bleck TP,et al.Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage[J].Neurocrit Care,2009,10(2):157-165.
[6] Stein M,Brokmeier L,Herrmann J,et al.Mean hemoglobin concentration after acute subarachnoid hemorrhage and the relation to outcome, mortality, vasospasm,and brain infarction[J].J Clin Neurosci,2015,22(3):530-534.
[7] Naidech AM,Jovanovic B,Wartenberg K,et al.Higher hemoglobin is associated with improved outcome after subarachnoid hemorrhage[J].Crit Care Med,2007,35(10):2383-2389.
[8] Naidech AM,Shaibani A,Garg RK,et al.Prospective,randomized trial of higher goal hemoglobin after subarachnoid hemorrhage[J].Neurocrit Care,2010,13(3):313-320.
[9] Tr1 S.Dhar R,diringer MN.factors associated with the development of anemia after subarachnoid hemorrhage[J].Neurocrit Care,2010,12(1):4-9.
[10] 郑匡,田作富,谭显西,等.早期治疗高分级动脉瘤性蛛网膜下腔出血的一年预后因素多中心研究[J].中华外科杂志,2016,54(7):534-539.
[11] 孟丽华.蛛网膜下腔出血继发贫血38例临床分析[J].现代医药卫生,2014,30(9):1349-1350.
[12] 任青,李静君,银锐,等.促血管生成素对动脉瘤性蛛网膜下腔出血预后关系[J].中华神经外科疾病研究杂志,2018,17(2):105-109.
[13] Oddo M,Milby A,Chen I,et al.Hemoglobin concentration and cerebral metabolism in patients with aneurysmal subarachnoid hemorrhage[J].Stroke,2009,40(4):1275-1281.
[14] Diringer MN,Bleck TP,Claude H3,et al.Critical care management of patients following aneurysmal subarachnoid hemorrhage:recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference[J].Neurocrit Care,2011,15(2):211-240.
[15] Rosenberg NF,Koht A,Naidech AM.Anemia and transfusion after aneurysmal subarachnoid hemorrhage[J].J Neurosurg Anesthesiol,2013,25(1):66-74.
[16] English SW,Fergusson D,Chassé M,et al.Canadian critical care trials group.aneurysmal subarachnoid Hemorrhage-Red blood cell transfusion and outcome(Sahara):a pilot randomised controlled trial protocol[J].BMJ Open,2016,6(12):e012623.
[17] Festic E,Rabinstein AA,Freeman WD,et al.Blood transfusion is an important predictor of hospital mortality among patients with aneurysmal subarachnoid hemorrhage[J].Neurocrit Care,2013,18(2):209-215.
[18] J SJ,Le Roux PD,Elliott JP,et al.Blood transfusion and increased risk for vasospasm and poor outcome after subarachnoid hemorrhage[J].Neurosurg,2004,101(1):1-7.
[19] Zhang J,Zhu Y,Zhou D,et al.Recombinant human erythropoietin(rhEPO)alleviates early brain injury following subarachnoid hemorrhage in rats:possible involvement of Nrf2-ARE pathway[J].Cytokine,2010,52(3):252-257.
[20] Tseng MY,Hutchinson PJ,Richards HK,et al.Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage:a Phase II randomized,double-blind,placebo-controlled trial[J].Clinical article.J Neurosurg,2009,111(1):171-180.